multiple system atrophy parkinsonian subtype
Conditions
Interventions
Active group:accelerated intermittent theta burst stimulation
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for MSA-P patients: 1. Meet the 2022 updated diagnostic criteria for multiple system atrophy (MSA) and be clinically diagnosed as "probable MSA" or "possible MSA" with predominant parkinsonian features (i.e., MSA-P subtype); 2. Hoehn-Yahr (H-Y) stage between 1 and 3; 3. Willing to undergo MRI scanning; 4. Agree to discontinue levodopa >12 hours, dopaminergic agonists >30 hours, and noradrenergic system-related medications >24 hours prior to MRI scanning; 5. Agree to refrain from consuming caffeine, strong tea, or other stimulant beverages >12 hours before scanning; 6. Voluntarily participate in the study and sign the informed consent form; 7. No significant cognitive impairment; 8. All participants are right-handed.
Exclusion criteria
Exclusion criteria: 1. Presence of clinically significant diseases or symptoms unrelated to MSA-P; 2. Metal implants (e.g., non-removable metal dentures, artificial eyes, cochlear implants, cardiac stents/valves, intrauterine devices, metal plates/screws, joint replacements, infusion pumps, post-aneurysm metal clips, pacemakers); 3. History of severe cardiovascular/cerebrovascular diseases, stroke, or respiratory disorders (e.g., bronchial asthma, COPD); 4. Significant cognitive decline; 5. Severe hearing/visual impairment or claustrophobia; 6. Inability to tolerate discontinuation of therapeutic medications for >12 hours; 7. Refusal to sign the informed consent form; 8. History of stroke, head trauma, hydrocephalus, brain tumors, intracranial hypertension, or neurosurgery; 9. Structural MRI findings indicating significant space-occupying lesions, defects, or large areas of chronic cerebral infarction; 10. Severe hepatic or renal dysfunction; 11. Substance abuse or addictive drug use; 12. Pregnancy or lactation; 13. Concurrent participation in other clinical trials; 14. Personal or family history of epilepsy; 15. Local discomfort or intolerance to TMS treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MDS-UPDRS-?;UMSARS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Functional connectivity;Hamilton Anxiety Scale;SCOPA-AUT;ALFF; | — |
Countries
China
Contacts
Public ContactTao Feng
Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Outcome results
None listed